• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach.

作者信息

Kodama Y, Kano T, Tamada R, Kumashiro R, Okamura T, Inokuchi K

出版信息

Jpn J Surg. 1982;12(4):244-8. doi: 10.1007/BF02469555.

DOI:10.1007/BF02469555
PMID:6811786
Abstract

Effectiveness of prophylactic extensive lymph node dissection (PELD) plus postoperative long term combination chemotherapy (PLCC) for patients with curatively resected gastric carcinoma was assessed in terms of the degree of serosal invasion and lymph node metastasis. Either the Group 1 and Group 2 lymph nodes were eradicated by PELD. PLCC included intermittent intravenous administration of mitomycin C (0.4 mg/kg intraoperatively followed by 0.2 mg/kg every 3 months) and oral administration of Tegafur (600-800 mg/day) and PSK (3.0 g/day), an immunostimulator, for as long a period as possible. PELD alone resulted in a cure when the malignancy was confined to the mucosal and muscular layers of the stomach as well as to the Group 1 lymph nodes. In cases when the carcinoma involved the serosa and/or the Group 2 lymph nodes, the 5 year survival rate was about 55 per cent the PELD and PLCC groups, such being significantly higher than about 27 per cent in the PELD alone group. Therefore, PELD plus PLCC is highly effective for advanced gastric carcinoma, under a condition of curative resection.

摘要

相似文献

1
Combined effect of prophylactic lymphadenectomy and long term combination chemotherapy for curatively resected carcinoma of the stomach.
Jpn J Surg. 1982;12(4):244-8. doi: 10.1007/BF02469555.
2
Postoperative long-term cancer chemotherapy (PLCC) extends life-span of non-curatively resected patients with stage IV gastric cancer.
Jpn J Surg. 1982;12(3):203-7. doi: 10.1007/BF02469588.
3
Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach.进展期胃癌术后长期癌症化疗的远期疗效
Jpn J Surg. 1981;11(4):291-6. doi: 10.1007/BF02468770.
4
Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection.接受根治性切除的胃癌患者术后长期癌症化疗的远期结果。
Jpn J Surg. 1983 Mar;13(2):112-6. doi: 10.1007/BF02469530.
5
[Surgery and adjuvant therapy of gastric cancer].
Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1555-63.
6
Prolonged survival of gastric cancer patients on a specific adjuvant chemotherapy.特定辅助化疗方案下胃癌患者的长期生存
Jpn J Surg. 1984 Sep;14(5):351-9. doi: 10.1007/BF02469540.
7
Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years.丝裂霉素C、氟尿嘧啶和云芝多糖K用于胃癌术后辅助免疫化疗。对579例患者随访五年的数据进行分析。
Jpn J Surg. 1988 Nov;18(6):681-6. doi: 10.1007/BF02471530.
8
[Effect of postoperative long-term cancer chemotherapy (PLCC) on non-curative gastric cancer of stage IV].
Gan To Kagaku Ryoho. 1982 Apr;9(4):710-5.
9
[An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric Cancer].克瘤宁与5-氟尿嘧啶辅助免疫化疗对接受根治性手术的胃癌患者的疗效(首次报告)——合作研究组的一项随机对照试验。胃癌PSK免疫化疗研究组
Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 1):2563-76.
10
Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection.辅助化疗可提高进展期胃癌患者根治性切除术后的长期生存率。
J Surg Oncol. 1990 Nov;45(3):169-72. doi: 10.1002/jso.2930450307.

引用本文的文献

1
Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review.药用蘑菇灵芝和云芝与细胞毒性抗癌药物之间的草药-药物相互作用:一项系统综述。
Chin Med. 2020 Jul 25;15:75. doi: 10.1186/s13020-020-00356-4. eCollection 2020.
2
Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.胃癌手术后口服抗癌药物辅助化疗 2 年的预后效果。
Surg Today. 2012 Aug;42(8):734-40. doi: 10.1007/s00595-012-0129-5. Epub 2012 Jan 27.
3
Prolonged survival of gastric cancer patients on a specific adjuvant chemotherapy.

本文引用的文献

1
USE OF THIO-TEPA AS AN ADJUVANT TO THE SURGICAL MANAGEMENT OF CARCINOMA OF THE STOMACH; V.A. COOPERATIVE SURGICAL ADJUVANT STUDY GROUP.硫替派作为胃癌手术治疗辅助剂的应用;退伍军人管理局合作手术辅助研究组
Cancer. 1965 Mar;18:291-7. doi: 10.1002/1097-0142(196503)18:3<291::aid-cncr2820180305>3.0.co;2-4.
2
Gastric carcinoma treated by chemotherapy after resection: a controlled study.
Am J Surg. 1980 Feb;139(2):197-9. doi: 10.1016/0002-9610(80)90253-6.
3
The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.胃癌外科与病理学研究的一般规则。第一部分。临床分类。
特定辅助化疗方案下胃癌患者的长期生存
Jpn J Surg. 1984 Sep;14(5):351-9. doi: 10.1007/BF02469540.
Jpn J Surg. 1981 Mar;11(2):127-39. doi: 10.1007/BF02468883.
4
Evaluation of extensive lymph node dissection for carcinoma of the stomach.胃癌广泛淋巴结清扫术的评估
World J Surg. 1981 Mar;5(2):241-8. doi: 10.1007/BF01658301.
5
Cancer of the stomach.胃癌
Am J Surg. 1981 Jan;141(1):10-4. doi: 10.1016/0002-9610(81)90003-9.
6
Late results of postoperative long term cancer chemotherapy for advanced carcinoma of the stomach.进展期胃癌术后长期癌症化疗的远期疗效
Jpn J Surg. 1981;11(4):291-6. doi: 10.1007/BF02468770.
7
End results of gastrectomy for gastric cancer: effect of extensive lymph node dissection.胃癌胃切除术的最终结果:广泛淋巴结清扫的效果
Surgery. 1970 Nov;68(5):753-8.
8
The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.肿瘤生长动力学在晚期实体瘤“根治性”化疗方案制定中的应用。
Cancer Res. 1969 Dec;29(12):2384-9.
9
Five-year survival rate of gastric cancer patients treated by gastrectomy, large dose of mitomycin-C, and-or allogeneic bone marrow transplantation.接受胃切除术、大剂量丝裂霉素-C和/或同种异体骨髓移植治疗的胃癌患者的五年生存率。
Gan. 1972 Oct;63(5):517-22.
10
Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach.
Cancer. 1969 Aug;24(2):223-8. doi: 10.1002/1097-0142(196908)24:2<223::aid-cncr2820240203>3.0.co;2-u.